scholarly journals Clinical Course and Treatment Response of Neuromyelitis Optica Spectrum Disease: An 8-Year Experience

2019 ◽  
Keyword(s):  
Treatment Response ◽  
Neuromyelitis Optica ◽  
Clinical Course

scholarly journals Coexisting Germline CHEK2 and Somatic BRAFV600E Mutations in Papillary Thyroid Cancer and Their Association with Clinicopathological Features and Disease Course

Cancers ◽  
2019 ◽  
Vol 11 (11) ◽  
pp. 1744 ◽  
Author(s):  
Danuta Gąsior-Perczak ◽  
Artur Kowalik ◽  
Agnieszka Walczyk ◽  
Monika Siołek ◽  
Krzysztof Gruszczyński ◽  
...  
Keyword(s):  
Treatment Response ◽  
Clinical Course ◽  
Repair Process ◽  
Clinicopathological Features ◽  
Older Age ◽  
Disease Outcome ◽  
Disease Course ◽  
Papillary Thyroid ◽  
Risk Treatment ◽  
Aggressive Clinical Course

BRAFV600E is the most common somatic mutation in papillary thyroid carcinoma (PTC) and the majority of evidence indicates that it is associated with an aggressive clinical course. Germline mutations of the CHEK2 gene impair the DNA damage repair process and increase the risk of PTC. Coexistence of both mutations is expected to be associated with poorer clinical course. We evaluated the prevalence of concomitant CHEK2 and BRAFV600E mutations and their associations with clinicopathological features, treatment response, and disease course in PTC patients. The study included 427 unselected PTC patients (377 women and 50 men) from one center. Relationships among clinicopathological features, mutation status, treatment response, and disease outcomes were assessed. Mean follow-up was 10 years. CHEK2 mutations were detected in 15.2% and BRAFV600E mutations in 64.2% patients. Neither mutation was present in 31.4% cases and both BRAFV600E and CHEK2 mutations coexisted in 10.8% patients. No significant differences in clinicopathological features, initial risk, treatment response, or disease outcome were detected among these patient groups. CHEK2 mutations were significantly associated with older age, while BRAFV600E was significantly associated with older age and extrathyroidal extension. The coexistence of both mutations was not associated with more aggressive clinicopathological features of PTC, poorer treatment response, or disease outcome.

Clinical course of neuromyelitis optica spectrum disorder in a moroccan cohort

2019 ◽  
Vol 30 ◽  
pp. 141-148 ◽  
Author(s):  
Anas Bennis ◽  
Hicham El Otmani ◽  
Nada Benkirane ◽  
Ilham Harrizi ◽  
Bouchra El Moutawakil ◽  
...  
Keyword(s):  
Neuromyelitis Optica ◽  
Clinical Course ◽  
Spectrum Disorder ◽  
Neuromyelitis Optica Spectrum Disorder

Duration of Untreated Illness as a Predictor of Treatment Response and Clinical Course in Generalized Anxiety Disorder

CNS Spectrums ◽  
2008 ◽  
Vol 13 (5) ◽  
pp. 415-422 ◽  
Author(s):  
A. Carlo Altamura ◽  
Bernardo Dell'Osso ◽  
Nazario D'Urso ◽  
Michela Russo ◽  
Sara Fumagalli ◽  
...  
Keyword(s):  
Anxiety Disorder ◽  
Treatment Response ◽  
Generalized Anxiety Disorder ◽  
Clinical Course ◽  
Time Effect ◽  
Generalized Anxiety ◽  
Pharmacologic Treatment ◽  
Group Effect ◽  
Duration Of Untreated Illness ◽  
The Impact

ABSTRACTIntroduction:The aim of the present study was to investigate the impact of the duration of untreated illness (DUI)—defined as the time elapsing between the onset of generalized anxiety disorder (GAD) and the first adequate pharmacologic treatment—on treatment response and clinical course in a sample of subjects with GAD.Methods:One hundred patients with GAD, diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-Text Revision criteria, were enrolled and their main demographic and clinical features collected. Patients were then treated with selective serotonin reuptake inhibitors or venlafaxine for 8 weeks in open-label conditions. Treatment response and other clinical variables were analyzed after dividing the sample into two groups according to DUI (DUI ≤12 months and DUI >12 months).Results:When the DUI was computed with respect to the first antidepressant treatment (DUI-AD), a higher improvement (Clinical Global Impressions-Severity of Illness scale) after the pharmacologic treatment was found in the group with a shorter DUI (analysis of variance with repeated measures: time effect F=654.975, P<.001; group effect: F=4.369, P=.O39). When computed with respect to the first treatment with benzodiazepines (DUI-BDZ), the two groups did not show any significant difference in treatment response (time effect: F=652.183, P<.001; group effect: F=0.009, P=.924). In addition, patients with a longer DUI (DUI-BDZ or DUI-AD) showed an earlier age at onset, a longer duration of illness and a higher rate of comorbid psychiatric disorders with onset later than GAD.Conclusion:Results from this preliminary study seem to suggest that a shorter DUI-AD may determine a better response to pharmacologic treatment in patients with GAD, and that a longer DUI (DUI-BDZ and DUI-AD) may be associated to a worse clinical course. Further investigation on the relationship between DUI and GAD is needed.

Progressive cerebral atrophy in neuromyelitis optica

2015 ◽  
Vol 21 (14) ◽  
pp. 1872-1875 ◽  
Author(s):  
Yoko Warabi ◽  
Toshiyuki Takahashi ◽  
Eiji Isozaki
Keyword(s):  
Neuromyelitis Optica ◽  
Basic Protein ◽  
Clinical Course ◽  
Elevated Serum ◽  
Cerebral Atrophy ◽  
Terminal Phase ◽  
Protein Levels ◽  
Secondary Progressive ◽  
Inflammatory Phase ◽  
Elderly Onset

We report two cases of neuromyelitis optica patients with progressive cerebral atrophy. The patients exhibited characteristic clinical features, including elderly onset, secondary progressive tetraparesis and cognitive impairment, abnormally elevated CSF protein and myelin basic protein levels, and extremely highly elevated serum anti-AQP-4 antibody titer. Because neuromyelitis optica pathology cannot switch from an inflammatory phase to the degenerative phase until the terminal phase, neuromyelitis optica rarely appears as a secondary progressive clinical course caused by axonal degeneration. However, severe intrathecal inflammation and massive destruction of neuroglia could cause a secondary progressive clinical course associated with cerebral atrophy in neuromyelitis optica patients.

The clinical course of neuromyelitis optica (Devic's syndrome)

Neurology ◽  
1999 ◽  
Vol 53 (5) ◽  
pp. 1107-1107 ◽  
Author(s):  
D. M. Wingerchuk ◽  
W. F. Hogancamp ◽  
P. C. O'Brien ◽  
B. G. Weinshenker
Keyword(s):  
Neuromyelitis Optica ◽  
Clinical Course ◽  
Devic’S Syndrome
Sign in / Sign up

Export Citation Format

Share Document